Results 101 to 110 of about 629,742 (317)

On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi‐Center Phase‐III Randomized Clinical Trials

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance.
Willem H. Collier   +11 more
wiley   +1 more source

BubR1 is frequently repressed in acute myeloid leukemia and its re-expression sensitizes cells to antimitotic therapy

open access: yesHaematologica, 2013
Spindle poison-based therapy is of only limited benefit in acute myeloid leukemia while lymphoblastic leukemia/lymphoma responds well. In this study, we demonstrated that the spindle assembly checkpoint protein BubR1 was down-regulated in the vast ...
Dominik Schnerch   +7 more
doaj   +1 more source

Testing the theory of immune selection in cancers that break the rules of transplantation [PDF]

open access: yes, 2009
Modification of cancer cells likely to reduce their immunogenicity, including loss or down-regulation of MHC molecules, is now well documented and has become the main support for the concept of immune surveillance.
Fassati, A.   +3 more
core   +1 more source

A Population‐Based Study on Childhood Aplastic Anemia—Incidence, Outcomes, and Health‐Related Quality of Life

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Childhood aplastic anemia (AA) is a rare disease, and both the disease itself and its treatment cause significant morbidity. We aimed to determine the contemporary incidence of childhood AA in Finland, to compare the clinical characteristics of AA against inherited bone marrow failure syndromes (IBMFS) and refractory cytopenia of ...
Lauri‐Matti Kulmala   +8 more
wiley   +1 more source

P468: MRD AS A BIOMARKER FOR RESPONSE TO DONOR LYMPHOCYTE INFUSION AFTER AL-LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

open access: yesHemaSphere, 2022
K. Teich   +15 more
doaj   +1 more source

Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico

open access: yesFrontiers in Oncology
BackgroundPrecursor B-cell acute lymphoblastic leukemia (pre-B ALL) is the most common pediatric cancer worldwide, with cure rates exceeding 85% in high-income countries.
Alberto Olaya-Vargas   +18 more
doaj   +1 more source

Cell separation and cryopreservation of cord blood fractions for immunotherapeutic applications [PDF]

open access: yes, 2014
In 2008 Anthony Nolan opened the UK’s first public umbilical cord blood (CB) bank (Anthony Nolan Cell Therapy Centre, ANCTC) in which CB is stored for haematopoietic stem cell (HSC) transplantation. Due to strict quality thresholds, the majority of units
Fry, LJ
core  

Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas   +3 more
wiley   +1 more source

Concepts of cell transplantation for spinal cord injury : a short overview [PDF]

open access: yes, 2005
In this short overview, I want to focus on two different standpoints in terms of cell transplantation therapy for spinal cord regeneration. In general, cell transplantation is performed with the purpose to supply new tissue components to the lesion.
Ide, Chizuka
core   +1 more source

Noninvasive in vivo tracking of mesenchymal stem cells and evaluation of cell therapeutic effects in a murine model using a clinical 3.0 T MRI [PDF]

open access: yes, 2013
Cardiac cell therapy with mesenchymal stem cells (MSCs) represents a promising treatment approach for end-stage heart failure. However, little is known about the underlying mechanisms and the fate of the transplanted cells. The objective of the presented
Neef, Klaus   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy